PrimeRFP SCOUT · Federal Contract Recompete Brief

75N93022C00060Fg-2101: a first-in-class LPXC inhibitor for — Forge Therapeutics Inc

Forge Therapeutics Inc holds $7.4M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 30 offers. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Niaid

Awarding office

Forge Therapeutics Inc

Recipient

Dec 31, 2026

PoP end

$12.1M

Obligated

$19.7M

Potential

541715

NAICS

AN12

PSC

NONE

Set-aside

30 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Forge Therapeutics Inc — $90

Contract facts

NONE

Contract number75N93022C00060

AgencyNational Institutes Of Health Niaid

Awarding officeNational Institutes Of Health Niaid

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentForge Therapeutics Inc

CAGE6XVV8

UEIZCWKWSWHAJD6

NAICS541715

PSCAN12

Place of performanceSAN DIEGO CA

Pricing typeCost Plus Fixed Fee

Extent competedFull And Open Competition

Related solicitationPHS-2021-1

PoP startSep 21, 2022

PoP end (current)Dec 31, 2026

Obligated$12.1M

Current value$12.1M

Potential value$19.7M

FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS. is a federal NONE award for National Institutes Of Health Niaid held by Forge Therapeutics Inc. Estimated value $19.7M ($12.1M obligated). Current period of performance ends Dec 31, 2026. Last award drew 30 bidders. Place of performance: SAN DIEGO CA. Related solicitation PHS-2021-1.

FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS.

Recompete timing

Public

● Expiring in 115 days

Current PoP ends Dec 31, 2026 (115 days remaining). Agencies typically plan 12–18 months ahead — at 3.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Forge Therapeutics Inc — $7.4M obligated across 1 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$7.4M · 100% of firm total

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N93022C00060?

75N93022C00060 (Fg-2101: a first-in-class LPXC inhibitor for) is a National Institutes Of Health Niaid award with a potential value of $19.7M, currently held by Forge Therapeutics Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N93022C00060?

National Institutes Of Health Niaid awarded 75N93022C00060 to Forge Therapeutics Inc (potential $19.7M).

Who is the incumbent on 75N93022C00060?

Forge Therapeutics Inc is the incumbent with $7.4M across 1 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.

When does Forge Therapeutics Inc’s 75N93022C00060 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on 75N93022C00060 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Apr 9, 2026